NCT05737615WithdrawnPhase 1
PET Imaging Using 64Cu-Tz-SarAr and hu5B1-TCO in People With Pancreatic, Colorectal, Bladder Cancer or Cancers With Elevated CA19.9
A Phase I Study of Pretargeted PET Imaging Using 64Cu-Tz-SarAr and a Trans-Cyclooctene-Modified Humanized 5B1 Immunoconjugate (hu5B1-TCO) in Patients With Pancreatic, Bladder Cancer, Gastrointestinal Malignancies or Solid Tumors With Elevated CA19-9
Source: ClinicalTrials.gov · Last updated 12 Aug 2026
Reason given: Study tracer is currently unavailable
Brief summary (registry, in English)
The purpose of this study is to find the highest safe dose of hu5B1-TCO and the best dosing schedule of hu5B1-TCO and 64Cu-Tz-SarAr for finding cancer cells that are CA19-9 positive. This study will also help to find out how much radiation the body is exposed to when 64Cu-Tz-SarAr is used, and provide information on the way the body absorbs, distributes, and gets rid of 64Cu-Tz-SarAr.
- Status (registry)
- Withdrawn
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 0 (actual)
- First submitted
- 10 Feb 2023
- Start date
- 10 Feb 2023
- Primary completion date
- 7 Aug 2026
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Diseases
- Pancreatic cancer, Bladder cancer, Colorectal cancer
- NCT number
- NCT05737615
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Major surgery other than diagnostic surgery within 4 weeks of Study Day 1
- Other on-going cancer therapy with investigational agents
Other illness
- Active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy
- History of anaphylactic reaction to human, or humanized, antibody
- Known history of HIV
- Psychiatric illness/social situations that would interfere with compliance with study requirements.
Other
- Patients will be excluded from the study if they fulfill any of the following criteria:
- Pregnant or currently breast-feeding
- Subjects and their partners with reproductive potential must agree to use an effective form of contraception during the study and for 1 week following the study treatment.
Who the study is looking for
- Patients will be eligible for enrollment if they fulfill the following criteria:
- Signed informed consent
- 18 years of age or older
- Histologically confirmed primary or metastatic pancreatic ductal adenocarcinoma/bladder carcinoma / gastrointestinal tumor reviewed at MSK - includes patients with biopsy-proven or high suspicion on imaging for pancreatic ductal adenocarcinoma (PDAC) or histologically confirmed, locally-advanced, or metastatic pancreatic ductal adenocarcinoma (PDAC) of
- Patient with solid tumors increased serum CA19-9 serum level greater than ULN or CA19-9 positive biopsy
- At least one lesion by CT or MRI ≥ 2 cm unless determined otherwise for presurgery subjects 5. ECOG performance status of 0 to 2 6. Adequate laboratory parameters including: i. Absolute neutrophil count (ANC) ≥1.5 x 109/L ii. Hemoglobin ≥ 9.0 g/dL iii. Platelet count >75,000/ mm3 iv. AST/SGOT, ALT/SGPT ≤2.5 x ULN, unless liver metastases are clearly present, then ≤5.0 x ULN v. Total bilirubin ≤ 1.5x the upper limit of normal unless considered due to Gilbert's syndrome in which case, ≤3x the upper limit of normal vi. Creatinine clearance (CLcr) (> 60 mL/min) estimated by the Cockcroft-Gault (C-G) equation or estimated glomerular filtration rate (eGFR) 10. Willingness to participate in collection of pharmacokinetic samples
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.